2025-524408-30-01招募中3 期
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard88 个研究点 分布在 5 个国家目标入组 292 人开始时间: 2026年3月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 292
- 试验地点
- 88
- 主要终点
- Event-free Survival (EFS)
研究概览
简要总结
To evaluate the efficacy of treatment intensification with docetaxel plus apalutamide and ADT, assessed by event-free survival, in metastatic hormone-sensitive prostate cancer patients who do not achieve deep PSA response (≤0.2 ng/ml or PSA90 response in combination with a PSA ≤4 ng/ml) after initial treatment with SOC ADT and apalutamide. Therefore, a non-deep PSA response is defined as PSA > 0.2 ng/ml in combination with a PSA response < 90%, or a PSA response ≥90% in combination with a PSA > 4 ng/ml.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Written informed consent. Each patient must sign an informed consent form (ICF) indicating that he understands the purpose of and procedures, required for the study, and is willing to participate in the study.
- •Patients who have not progressed on apalutamide.
- •Patients that are tolerating adequately apalutamide 240 mg daily and with no toxicity higher than G1 at inclusion.
- •Be able to swallow whole apalutamide film-coated tablets.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Clinical laboratory values at screening: a. hemoglobin ≥10.0 g/dL, b. absolute neutrophil count ≥1.5 × 109/L, c. platelet count ≥100 × 109/L, The patient must not have received any growth factor within 4 weeks or a blood transfusion within 7 days of the hematology laboratory sample obtained at screening d. serum alanine aminotransferase and/or aspartate transaminase ≤1.5 × the upper limit of normal (ULN), e. total bilirubin ≤ ULN, f. creatinine ≤2.0 × ULN,
- •Sexually active men must agree to use an external condom as an effective barrier method and refrain from sperm donation, and their female partners of childbearing potential must practice a highly effective method of contraception during and for 3 months after treatment with apalutamide and for 6 months after treatment with docetaxel.
- •Patient must be a man ≥18 years of age.
- •Histologically or cytologically confirmed adenocarcinoma of prostate.
- •Metastatic hormone-sensitive prostate cancer.
- •PSA >5 ng/ml at diagnosis of metastatic disease.
- •Patients eligible to continue treatment with apalutamide and ADT and without contra-indication to receive docetaxel.
- •Patients with at least 24 weeks and no more than 30 weeks of apalutamide.
- •Patients with a maximum of 12 weeks ADT before apalutamide initiation.
- •Lack of achievement of deep PSA response after 24 weeks and no more than 30 weeks of apalutamide. Deep PSA response is defined as PSA ≤ 0.2 ng/ml or PSA response ≥ 90% in combination with a PSA ≤4 ng/ml. Therefore, a non-deep PSA response is defined as PSA > 0.2 ng/ml in combination with a PSA response < 90%, or a PSA response ≥90% in combination with a PSA > 4 ng/ml.
排除标准
- •Presence of neuroendocrine histology.
- •Apalutamide treatment started more than 30 weeks before inclusion.
- •Progression disease by any means, including radiographic, clinical or serological at inclusion.
- •Patient who achieves deep PSA response on apalutamide treatment before randomization
- •Previous androgen-pathway receptor inhibitors, including enzalutamide, darolutamide, abiraterone or other ARPI. Previous treatment with first generation antiandrogens (i.e. bicalutamide) is allowed.
- •Chemotherapy or immunotherapy for prostate cancer before randomization.
- •Treatment with radiotherapy (external-beam radiation therapy, brachytherapy, or radiopharmaceuticals) within 2 weeks before randomization.
- •Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs.
- •Contraindication to both computed tomography and magnetic resonance imaging contrast agent
- •Prolonged QT interval defined as QTcF ≥ 480 ms at screening, based on the mean of triplicate 12-lead ECGs performed after at least 5 minutes of rest. Patients with congenital long QT syndrome will also be excluded.
- •Any of the following within 6 months before randomization: a. stroke, b. myocardial infarction, c. severe or unstable angina pectoris, d. uncontrolled arrhythmia, e. coronary or peripheral artery bypass graft, or f. congestive heart failure (New York Heart Association class III or IV)
- •Peripheral neuropathy ≥ grade
- •Uncontrolled hypertension, indicated by resting systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg despite medical management.
- •Prior malignancy, except for adequately treated basal-cell or squamous-cell carcinoma of the skin or superficial bladder cancer that had not spread behind the connective-tissue layer (i.e., stage pTis, pTa, or pT1) or any cancer for which treatment had been completed ≥5 years before randomization and from which the patient was disease-free.
- •A gastrointestinal disorder or procedure that was expected to interfere significantly with absorption of study drug.
- •Active viral hepatitis, known human immunodeficiency virus infection with detectable viral load, or chronic liver disease requiring treatment.
- •Previous (within 28 days before the start of study drug or 5 half-lives of the investigational treatment of the previous study, whichever was longer) or concomitant participation in another clinical study with investigational medicinal products.
- •Any other serious or unstable illness or medical, social, or psychological condition that could jeopardize the safety of the patient and/or their compliance with study procedures or might interfere with their participation in the study or evaluation of the study results.
研究组 & 干预措施
Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Test
干预措施: Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung (Drug)
Erleada 240 mg film-coated tablets, Erleada 60 mg film-coated tablets
Test
干预措施: Erleada 60 mg film-coated tablets (Drug)
Erleada 240 mg film-coated tablets, Erleada 60 mg film-coated tablets
Test
干预措施: Erleada 240 mg film-coated tablets (Drug)
结局指标
主要结局
Event-free Survival (EFS)
Event-free Survival (EFS)
次要结局
- Adverse events, serious adverse events, adverse events leading to treatment discontinuation and death.
- Change from baseline over time in each of the subscales of FACT-P, BPI-SF interference subscale and BFI .
- PSA progression-free survival
- Overall survival
- Time to subsequent treatment
- Time to castration resistance
- Radiographic progression-free survival (rPFS)
- Symptomatic skeletal event free survival
- Deep and/or ultradeep PSA response rate at 6 months
- Time to initiate opioid use (≥ 7 days)
研究者
Enrique González-Billalabeitia
Scientific
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
研究点 (88)
Loading locations...
相似试验
已完成
3 期
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200)Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation2023-508214-42-00Amgen Inc.362
招募中
3 期
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)2024-513867-19-00Memorial Sloan Kettering Cancer Center285
招募中
1 期
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57
尚未招募
2 期
A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNCT07354984Sun Yat-sen University30
招募中
3 期
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric CancerNCT07366528Ruijin Hospital387